<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Clinical use of oral disease-modifying therapies for multiple sclerosis</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Clinical use of oral disease-modifying therapies for multiple sclerosis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Clinical use of oral disease-modifying therapies for multiple sclerosis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael J Olek, DO</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Ellen Mowry, MD, MCR</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Francisco González-Scarano, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John F Dashe, MD, PhD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 17, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H3591183525"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Multiple sclerosis (MS) is an immune-mediated inflammatory demyelinating disease of the central nervous system that is a leading cause of disability in young adults. Disease-modifying therapies (DMTs) for MS are drugs that effectively reduce the relapse rate for patients with MS.</p><p>The indications, efficacy, dose, administration, monitoring, and adverse effects of oral DMTs for MS are discussed in this topic review. Other DMTs for MS are reviewed elsewhere:</p><p class="bulletIndent1"><span class="glyph">●</span>Monoclonal antibodies for MS (see  <a class="medical medical_review" href="/z/d/html/143122.html" rel="external">"Clinical use of monoclonal antibody disease-modifying therapies for multiple sclerosis"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Platform injection therapies (see  <a class="medical medical_review" href="/z/d/html/129091.html" rel="external">"Overview of disease-modifying therapies for multiple sclerosis", section on 'Platform therapies'</a>)</p><p></p><p class="headingAnchor" id="H2142297694"><span class="h1">CHOOSING THERAPY</span><span class="headingEndMark"> — </span>There are multiple disease-modifying therapies (DMTs) for MS, including older platform injection therapies, monoclonal antibodies, and oral agents.</p><p>Oral DMTs for MS include fumarates (<a class="drug drug_general" data-topicid="88899" href="/z/d/drug information/88899.html" rel="external">dimethyl fumarate</a>, <a class="drug drug_general" data-topicid="123109" href="/z/d/drug information/123109.html" rel="external">diroximel fumarate</a>, and <a class="drug drug_general" data-topicid="128079" href="/z/d/drug information/128079.html" rel="external">monomethyl fumarate</a>), sphingosine 1-phosphate receptor (S1PR) modulators (<a class="drug drug_general" data-topicid="16078" href="/z/d/drug information/16078.html" rel="external">fingolimod</a>, <a class="drug drug_general" data-topicid="120818" href="/z/d/drug information/120818.html" rel="external">siponimod</a>, <a class="drug drug_general" data-topicid="127521" href="/z/d/drug information/127521.html" rel="external">ozanimod</a>, and <a class="drug drug_general" data-topicid="131158" href="/z/d/drug information/131158.html" rel="external">ponesimod</a>), a purine nucleoside analog (<a class="drug drug_general" data-topicid="9272" href="/z/d/drug information/9272.html" rel="external">cladribine</a>), and a pyrimidine synthesis inhibitor (<a class="drug drug_general" data-topicid="86616" href="/z/d/drug information/86616.html" rel="external">teriflunomide</a>) [<a href="#rid1">1</a>]. In general, oral DMTs may be preferred for patients with less active disease and for patients who value convenience using a self-administered oral medication compared with medications requiring injections or infusions, although efficacy appears to vary amongst them, and definitive benefit for using higher-efficacy therapies instead of an escalation approach remains to be established.</p><p>Thus, there is no uniform method for choosing the best DMT for an individual patient. The choice of a specific agent for patients with MS should be individualized according to disease activity, comorbid conditions, and patient values and preferences  (<a class="graphic graphic_algorithm graphicRef102519" href="/z/d/graphic/102519.html" rel="external">algorithm 1</a>).</p><p>The use of DMTs for specific clinical situations is discussed in separate topic reviews:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/1691.html" rel="external">"Management of clinically and radiologically isolated syndromes suggestive of multiple sclerosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/1687.html" rel="external">"Initial disease-modifying therapy for relapsing-remitting multiple sclerosis in adults"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/129095.html" rel="external">"Indications for switching or stopping disease-modifying therapy for multiple sclerosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/1686.html" rel="external">"Treatment of secondary progressive multiple sclerosis in adults"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/128298.html" rel="external">"Treatment of primary progressive multiple sclerosis in adults"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/135221.html" rel="external">"Multiple sclerosis: Pregnancy planning"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/138599.html" rel="external">"Multiple sclerosis: Pregnancy and postpartum care"</a>.)</p><p></p><p>The treatment of acute MS exacerbations is also reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/1698.html" rel="external">"Treatment of acute exacerbations of multiple sclerosis in adults"</a>.)</p><p class="headingAnchor" id="H2809497759"><span class="h1">FUMARATES</span><span class="headingEndMark"> — </span>Fumarates may have neuroprotective and immunomodulatory properties through activation of the nuclear factor (erythroid-derived 2)-like 2 (Nrf2) pathway. However, the exact mechanism of therapeutic effect in MS is uncertain.</p><p class="headingAnchor" id="H3235104888"><span class="h2">Dimethyl fumarate</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="88899" href="/z/d/drug information/88899.html" rel="external">Dimethyl fumarate</a> is an oral fumarate that is metabolized to <a class="drug drug_general" data-topicid="128079" href="/z/d/drug information/128079.html" rel="external">monomethyl fumarate</a>, its active metabolite.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indications</strong> – <a class="drug drug_general" data-topicid="88899" href="/z/d/drug information/88899.html" rel="external">Dimethyl fumarate</a> is indicated for the treatment of relapsing forms of MS, including clinically isolated syndromes (CIS), relapsing-remitting multiple sclerosis (RRMS), and active secondary progressive multiple sclerosis (SPMS). It is contraindicated for patients with known hypersensitivity to dimethyl fumarate.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dose and administration</strong> – The starting dose for oral <a class="drug drug_general" data-topicid="88899" href="/z/d/drug information/88899.html" rel="external">dimethyl fumarate</a> is 120 mg given twice daily. After seven days, the dose should be increased to 240 mg given twice daily. It is available in 120 and 240 mg preparations. Taking the medication with food may decrease the rate of gastrointestinal upset.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects</strong> – The most common side effects of <a class="drug drug_general" data-topicid="88899" href="/z/d/drug information/88899.html" rel="external">dimethyl fumarate</a> are flushing and gastrointestinal symptoms, including diarrhea, nausea, and abdominal pain.</p><p></p><p class="bulletIndent1">There are case reports of patients taking dimethyl fumarates for MS or psoriasis who developed progressive multifocal leukoencephalopathy (PML), including those with and without lymphocytopenia, although lymphocytopenia is considered the major risk factor for PML beyond JC polyomavirus (JCV) serostatus [<a href="#rid2">2-6</a>]. Other reported adverse events include anaphylaxis and angioedema, herpes zoster and other serious opportunistic infections, hepatotoxicity, and serious gastrointestinal reactions including perforation, ulceration, hemorrhage, and obstruction [<a href="#rid6">6</a>]. (See  <a class="medical medical_review" href="/z/d/html/1694.html" rel="external">"Progressive multifocal leukoencephalopathy (PML): Epidemiology, clinical manifestations, and diagnosis"</a>.)</p><p></p><p class="bulletIndent1">Liver injury associated with <a class="drug drug_general" data-topicid="88899" href="/z/d/drug information/88899.html" rel="external">dimethyl fumarate</a> is manifested by elevated serum aminotransferase and bilirubin levels, with onset from a few days to several months after starting treatment [<a href="#rid7">7</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Screening and monitoring</strong> – Treatment with <a class="drug drug_general" data-topicid="88899" href="/z/d/drug information/88899.html" rel="external">dimethyl fumarate</a> may decrease lymphocyte counts, so patients should have a complete blood count obtained before starting the medication, no longer than six months after starting treatment (eg, months 1, 2, 3, and 6 after starting treatment), and at least every six months or as clinically indicated during treatment.</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="88899" href="/z/d/drug information/88899.html" rel="external">Dimethyl fumarate</a> should be discontinued if lymphocytopenia develops, although the exact cutpoint that defines an unacceptably low count is not established. However, lymphocyte counts &lt;0.8 x 10<sup>9</sup>/L may raise concern despite the uncertainty of the cutpoint. Dimethyl fumarate risk has not been specifically studied in patients with pre-existing low lymphocyte counts.</p><p></p><p class="bulletIndent1">Serum aminotransferase, alkaline phosphatase, and total bilirubin levels should be obtained prior to and during treatment as clinically indicated; the drug should be discontinued if clinically significant liver injury occurs.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy</strong> – In the CONFIRM and DEFINE trials, an oral formulation of <a class="drug drug_general" data-topicid="88899" href="/z/d/drug information/88899.html" rel="external">dimethyl fumarate</a> (called BG-12 at the time of these trials) significantly reduced relapse rates and the development of new brain lesions on magnetic resonance imaging (MRI) in patients with active MS [<a href="#rid8">8-10</a>], and results from the DEFINE trial suggest that dimethyl fumarate reduces the rate of disability progression [<a href="#rid9">9</a>].</p><p></p><p class="bulletIndent1">The CONFIRM trial randomly assigned over 1400 adults with RRMS to treatment with oral <a class="drug drug_general" data-topicid="88899" href="/z/d/drug information/88899.html" rel="external">dimethyl fumarate</a> at 480 mg daily in two divided doses, oral dimethyl fumarate at 720 mg daily in three divided doses, subcutaneous <a class="drug drug_general" data-topicid="8490" href="/z/d/drug information/8490.html" rel="external">glatiramer acetate</a> 20 mg daily, or placebo in a 1:1:1:1 ratio [<a href="#rid8">8</a>]. At two years compared with placebo, the annualized relapse rate was significantly lower in groups assigned to dimethyl fumarate 480 mg daily, dimethyl fumarate 720 mg daily, and glatiramer acetate (0.22, 0.20, and 0.29, respectively, versus 0.40 for placebo). In addition, the number of new or enlarging brain lesions by MRI was significantly reduced for groups assigned to both doses of dimethyl fumarate and to glatiramer acetate compared with placebo. There was a trend towards lower rates of disability progression with dimethyl fumarate and glatiramer acetate treatment, but the differences compared with placebo were not statistically significant. In post hoc analyses comparing dimethyl fumarate with glatiramer acetate, there were no significant differences in relapse rates or MRI outcomes.</p><p></p><p class="bulletIndent1">The DEFINE trial randomly assigned over 1200 adults with RRMS to oral <a class="drug drug_general" data-topicid="88899" href="/z/d/drug information/88899.html" rel="external">dimethyl fumarate</a> at 480 mg daily in two divided doses, oral dimethyl fumarate at 720 mg daily in three divided doses, or placebo [<a href="#rid9">9</a>]. At two years, treatment with dimethyl fumarate 480 mg daily and 720 mg daily resulted in significant reductions in the proportion of patients who had a relapse (27 and 26 percent, versus 46 percent for placebo), the annualized relapse rate (0.17 and 0.19, versus 0.36 for placebo), and the proportion of patients with progression of disability (16 and 18 percent, versus 27 percent for placebo). Dimethyl fumarate treatment also significantly reduced the number of new brain lesions on MRI.</p><p></p><p class="headingAnchor" id="H4038902564"><span class="h2">Diroximel fumarate</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="123109" href="/z/d/drug information/123109.html" rel="external">Diroximel fumarate</a> is an oral fumarate and bioequivalent to <a class="drug drug_general" data-topicid="88899" href="/z/d/drug information/88899.html" rel="external">dimethyl fumarate</a>; it is rapidly metabolized to <a class="drug drug_general" data-topicid="128079" href="/z/d/drug information/128079.html" rel="external">monomethyl fumarate</a>, its major active metabolite. The approval of diroximel fumarate was based mainly upon bioequivalence, safety, and efficacy data for dimethyl fumarate; both are metabolized to monomethyl fumarate [<a href="#rid11">11</a>]. (See <a class="local">'Dimethyl fumarate'</a> above.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indications </strong>– <a class="drug drug_general" data-topicid="123109" href="/z/d/drug information/123109.html" rel="external">Diroximel fumarate</a> is indicated for the treatment of relapsing forms of MS, including CIS, RRMS, and active SPMS [<a href="#rid11">11,12</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dose and administration</strong> – Oral <a class="drug drug_general" data-topicid="123109" href="/z/d/drug information/123109.html" rel="external">diroximel fumarate</a> is started at 231 mg twice daily for seven days, and then increased to the maintenance dose of 462 mg twice daily [<a href="#rid11">11</a>]. The drug should not be taken with a high-fat, high-calorie meal or snack.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects</strong> – The adverse effect profile of <a class="drug drug_general" data-topicid="123109" href="/z/d/drug information/123109.html" rel="external">diroximel fumarate</a> is similar to that of <a class="drug drug_general" data-topicid="88899" href="/z/d/drug information/88899.html" rel="external">dimethyl fumarate</a>, which has the same active metabolite (see <a class="local">'Dimethyl fumarate'</a> above) [<a href="#rid11">11</a>]. The most common adverse effects are flushing, abdominal pain, diarrhea, and nausea. Uncommon but serious adverse effects may include anaphylaxis, angioedema, opportunistic infections (eg, PML, herpes zoster virus), lymphopenia, liver injury, and gastrointestinal reactions including perforation, ulceration, hemorrhage, and obstruction [<a href="#rid11">11</a>].</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="123109" href="/z/d/drug information/123109.html" rel="external">Diroximel fumarate</a> is postulated to have fewer gastrointestinal symptoms compared with <a class="drug drug_general" data-topicid="88899" href="/z/d/drug information/88899.html" rel="external">dimethyl fumarate</a>. In a five-week randomized trial of patients with RRMS comparing diroximel fumarate with dimethyl fumarate, the group assigned to diroximel fumarate had lower rates of gastrointestinal adverse events (35 percent versus 49 percent) [<a href="#rid13">13</a>], possibly because the moiety attached to <a class="drug drug_general" data-topicid="128079" href="/z/d/drug information/128079.html" rel="external">monomethyl fumarate</a> (the active ingredient) is less enterotoxic in this form of the medication.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Screening and monitoring</strong> – Before starting <a class="drug drug_general" data-topicid="123109" href="/z/d/drug information/123109.html" rel="external">diroximel fumarate</a>, patients should have baseline tests to include complete blood count with lymphocyte count, serum aminotransferase, alkaline phosphatase, and total bilirubin levels [<a href="#rid11">11</a>].</p><p></p><p class="bulletIndent1">During therapy, patients should have a complete blood cell count, including lymphocyte count, six months after starting <a class="drug drug_general" data-topicid="123109" href="/z/d/drug information/123109.html" rel="external">diroximel fumarate</a> (or months 1, 2, 3, and 6 after starting treatment) and every six months thereafter. Serum aminotransferase, alkaline phosphatase, and total bilirubin levels are monitored during treatment as clinically indicated.</p><p></p><p class="headingAnchor" id="H69779963"><span class="h2">Monomethyl fumarate</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="128079" href="/z/d/drug information/128079.html" rel="external">Monomethyl fumarate</a> is another bioequivalent alternative to <a class="drug drug_general" data-topicid="88899" href="/z/d/drug information/88899.html" rel="external">dimethyl fumarate</a>. The approval was based upon bioequivalence, safety, and efficacy data for dimethyl fumarate, which is metabolized to monomethyl fumarate [<a href="#rid14">14</a>]. (See <a class="local">'Dimethyl fumarate'</a> above.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indications </strong>– <a class="drug drug_general" data-topicid="128079" href="/z/d/drug information/128079.html" rel="external">Monomethyl fumarate</a> is indicated for the treatment of relapsing forms of MS, including CIS, RRMS, and active SPMS [<a href="#rid15">15</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dose and administration</strong> – <a class="drug drug_general" data-topicid="128079" href="/z/d/drug information/128079.html" rel="external">Monomethyl fumarate</a> is started at 95 mg twice daily orally for seven days, and then increased to the maintenance dose of 190 mg twice daily [<a href="#rid15">15</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects</strong> – The adverse effect profile of <a class="drug drug_general" data-topicid="128079" href="/z/d/drug information/128079.html" rel="external">monomethyl fumarate</a> is the same as that of <a class="drug drug_general" data-topicid="88899" href="/z/d/drug information/88899.html" rel="external">dimethyl fumarate</a>, the prodrug of monomethyl fumarate (see <a class="local">'Dimethyl fumarate'</a> above) [<a href="#rid15">15</a>]. The most common adverse effects are flushing, abdominal pain, diarrhea, and nausea. Uncommon but serious adverse effects may include anaphylaxis, angioedema, opportunistic infections (eg, PML, herpes zoster virus), lymphopenia, and liver injury; serious gastrointestinal reactions including perforation, ulceration, hemorrhage, and obstruction have been reported with other fumarates [<a href="#rid15">15</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Screening and monitoring</strong> – Before starting <a class="drug drug_general" data-topicid="128079" href="/z/d/drug information/128079.html" rel="external">monomethyl fumarate</a>, patients should have baseline tests to include complete blood count with lymphocyte count, serum aminotransferase, alkaline phosphatase, and total bilirubin levels [<a href="#rid15">15</a>].</p><p></p><p class="bulletIndent1">During therapy, patients should have a complete blood count, including lymphocyte count, within six months after starting <a class="drug drug_general" data-topicid="128079" href="/z/d/drug information/128079.html" rel="external">monomethyl fumarate</a> (or months 1, 2, 3, and 6 after starting treatment) and every six months thereafter, as clinically indicated. Serum aminotransferase, alkaline phosphatase, and total bilirubin levels are monitored during treatment as clinically indicated.</p><p></p><p class="headingAnchor" id="H234439976"><span class="h1">S1PR MODULATORS</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="16078" href="/z/d/drug information/16078.html" rel="external">Fingolimod</a>, <a class="drug drug_general" data-topicid="120818" href="/z/d/drug information/120818.html" rel="external">siponimod</a>, <a class="drug drug_general" data-topicid="127521" href="/z/d/drug information/127521.html" rel="external">ozanimod</a>, and <a class="drug drug_general" data-topicid="131158" href="/z/d/drug information/131158.html" rel="external">ponesimod</a> are sphingosine 1-phosphate receptor (S1PR) modulators used for the treatment of MS [<a href="#rid16">16</a>]. These drugs work by preventing lymphocyte egress from lymph nodes, which is thought to limit migration of inflammatory cells into the central nervous system.</p><p class="headingAnchor" id="H2703513193"><span class="h2">Fingolimod</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="16078" href="/z/d/drug information/16078.html" rel="external">Fingolimod</a> is a sphingosine analog that modulates the S1PR and thereby alters lymphocyte migration, resulting in sequestration of lymphocytes in lymph nodes [<a href="#rid17">17</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indications</strong> – <a class="drug drug_general" data-topicid="16078" href="/z/d/drug information/16078.html" rel="external">Fingolimod</a> is indicated for the treatment of relapsing forms of MS, including clinically isolated syndromes (CIS), relapsing-remitting multiple sclerosis (RRMS), and active secondary progressive multiple sclerosis (SPMS), in patients age 10 years and older [<a href="#rid18">18,19</a>].</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="16078" href="/z/d/drug information/16078.html" rel="external">Fingolimod</a> is <strong>contraindicated</strong> in patients with recent (within six months) myocardial infarction, unstable angina, stroke, transient ischemic attack (TIA), or heart failure; a history of second- or third-degree atrioventricular block or sinus node dysfunction (unless treated with a pacemaker); a prolonged QT interval ≥500 milliseconds at baseline; and treatment with antiarrhythmic drugs [<a href="#rid18">18</a>]. We suggest <strong>not</strong> using fingolimod to treat patients who have diabetes because they are at increased risk for macular edema, which has been reported in association with fingolimod treatment. In addition, the trials of fingolimod excluded patients with diabetes.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dose and administration</strong> – For adults and children (age 10 years and older) weighing more than 40 kg, the dose of oral <a class="drug drug_general" data-topicid="16078" href="/z/d/drug information/16078.html" rel="external">fingolimod</a> is 0.5 mg once daily [<a href="#rid18">18</a>]. For children age ≥10 years weighing ≤40 kg, the dose is 0.25 mg orally, once daily.</p><p></p><p class="bulletIndent1">The first dose, and doses following therapy interruption longer than 14 days, should be given in a setting where symptomatic bradycardia can be managed [<a href="#rid18">18</a>]. At treatment initiation, baseline pulse and blood pressure should be measured. These measurements should be repeated hourly for six hours after the first dose while the patient is observed for signs of bradycardia or atrioventricular block, and an electrocardiogram (ECG) should be obtained at the end of the six-hour observation period. For patients who are at higher risk for bradycardia or who may not tolerate it, cardiovascular monitoring should be extended overnight using continuous ECG monitoring. Patients who develop symptomatic bradycardia or atrioventricular block (second degree or higher) should be managed appropriately and monitored with continuous ECG until the symptoms resolve.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects</strong> – The most common adverse effects associated with <a class="drug drug_general" data-topicid="16078" href="/z/d/drug information/16078.html" rel="external">fingolimod</a> are headache, elevated liver enzymes, diarrhea, cough, flu, sinusitis, back pain, abdominal pain, and pain in the arms or legs [<a href="#rid18">18,19</a>]. Fingolimod treatment has been associated with an increased risk of bradyarrhythmia and atrioventricular block (potentially fatal), increased blood pressure, macular edema, liver injury, diminished respiratory function, tumor development, and opportunistic infections [<a href="#rid20">20-23</a>]. The immunomodulating and lymphocytopenic effects of fingolimod increase the risk of viral and fungal infection, including varicella zoster virus (VZV) infections [<a href="#rid24">24-26</a>], cryptococcal meningoencephalitis [<a href="#rid27">27</a>], and disseminated cryptococcus [<a href="#rid28">28</a>]. Rare cases of progressive multifocal leukoencephalopathy (PML) and PML with immune reconstitution inflammatory syndrome (PML-IRIS) have been reported in patients with and without prior immunosuppressant treatment [<a href="#rid29">29-31</a>]. All reported PML cases occurred after 19 months of fingolimod treatment.</p><p></p><p class="bulletIndent1">There is observational evidence that paradoxical worsening of MS disease activity can occur <strong>after stopping</strong> <a class="drug drug_general" data-topicid="16078" href="/z/d/drug information/16078.html" rel="external">fingolimod</a> treatment [<a href="#rid32">32,33</a>]. In addition, paradoxical worsening of MS disease activity (some following cessation of <a class="drug drug_general" data-topicid="10252" href="/z/d/drug information/10252.html" rel="external">natalizumab</a>) or the development of tumefactive MS lesions has been reported <strong>during</strong> fingolimod treatment [<a href="#rid34">34-36</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Screening and monitoring</strong> – Before starting <a class="drug drug_general" data-topicid="16078" href="/z/d/drug information/16078.html" rel="external">fingolimod</a>, patients should have the following baseline studies [<a href="#rid18">18,19</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Complete blood count and liver function test results within six months</p><p class="bulletIndent2"><span class="glyph">•</span>ECG</p><p class="bulletIndent2"><span class="glyph">•</span>Ophthalmologic examination</p><p class="bulletIndent2"><span class="glyph">•</span>Varicella serology, and VZV vaccination if antibody negative, for patients without a confirmed history of VZV infection or prior vaccination; <a class="drug drug_general" data-topicid="16078" href="/z/d/drug information/16078.html" rel="external">fingolimod</a> should not be started until one month after vaccination</p><p class="bulletIndent2"><span class="glyph">•</span>Skin examination</p><p></p><p class="bulletIndent1">Females of childbearing potential should be informed of risk for adverse fetal outcomes; however, a higher rate of fetal abnormalities was not detected among infants exposed to <a class="drug drug_general" data-topicid="16078" href="/z/d/drug information/16078.html" rel="external">fingolimod</a> in pregnancy registries [<a href="#rid37">37</a>].</p><p></p><p class="bulletIndent1">With <a class="drug drug_general" data-topicid="16078" href="/z/d/drug information/16078.html" rel="external">fingolimod</a> treatment, the following tests and practices are recommended [<a href="#rid18">18</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Monitor for infection during and for two months after stopping <a class="drug drug_general" data-topicid="16078" href="/z/d/drug information/16078.html" rel="external">fingolimod</a> treatment; patients with subacute new or worsening symptoms should be evaluated for possible PML with brain MRI and polymerase chain reaction (PCR) analysis of cerebrospinal fluid for the presence of JC polyomavirus (JCV) deoxyribonucleic acid (DNA).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>We check a complete blood count with differential including lymphocyte count before starting treatment and every six months during treatment. <a class="drug drug_general" data-topicid="16078" href="/z/d/drug information/16078.html" rel="external">Fingolimod</a> is expected to lower the lymphocyte count by its mechanism of action. Many experts suggest consideration of therapy switch if the lymphocyte count decreases below 200 cells/microL or even 400 cells/microL.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Live attenuated vaccines should be avoided during and for two months after stopping <a class="drug drug_general" data-topicid="16078" href="/z/d/drug information/16078.html" rel="external">fingolimod</a> treatment [<a href="#rid18">18,24</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Ophthalmologic examination should be repeated three to four months after starting <a class="drug drug_general" data-topicid="16078" href="/z/d/drug information/16078.html" rel="external">fingolimod</a>, and routinely in patients with diabetes mellitus or a history of uveitis.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A skin examination at baseline and periodically during treatment is recommended to screen for evidence of cancerous or precancerous skin lesions.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Pulmonary function tests with spirometry and diffusion lung capacity for carbon monoxide (DLCO) should be obtained if indicated clinically.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Liver function tests should be monitored for patients with symptoms suggestive of hepatic dysfunction; some experts monitor every six months during treatment even in the absence of symptoms.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Monitor blood pressure during treatment.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="16078" href="/z/d/drug information/16078.html" rel="external">Fingolimod</a> is a possible teratogen and should be stopped two months prior to conception, with consideration of switching to an anti-CD20 monoclonal antibody disease-modifying therapy (DMT) two or more months before attempts to conceive to avoid MS rebound [<a href="#rid38">38</a>]. (See  <a class="medical medical_review" href="/z/d/html/135221.html" rel="external">"Multiple sclerosis: Pregnancy planning", section on 'Preconception planning and care'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Stopping <a class="drug drug_general" data-topicid="16078" href="/z/d/drug information/16078.html" rel="external">fingolimod</a> has been associated, in our experience, with rebound of MS in some patients, so appropriate counseling and management should be provided before cessation of medication.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy</strong> – There is evidence from several randomized controlled trials that <a class="drug drug_general" data-topicid="16078" href="/z/d/drug information/16078.html" rel="external">fingolimod</a> is effective in reducing the relapse rate in patients with RRMS [<a href="#rid39">39</a>]. The FREEDOMS trial randomly assigned 1272 adults with RRMS to treatment in a 1:1:1 ratio with either oral fingolimod (0.5 mg daily or 1.25 mg daily) or placebo [<a href="#rid20">20</a>]. At 24 months, the annualized relapse rate was significantly reduced on intention-to-treat analysis for both the high and low fingolimod groups compared with placebo (0.18, 0.16, and 0.40, respectively). In addition, fingolimod treatment resulted in statistically significant reductions in both the risk of sustained disability progression and new lesions on brain MRI. In the open-label FREEDOMS extension trial, long-term fingolimod treatment was associated with reduced relapse rates and disability progression [<a href="#rid40">40</a>].</p><p></p><p class="bulletIndent1">The TRANSFORMS trial randomly assigned over 1200 adults with RRMS to treatment with either oral <a class="drug drug_general" data-topicid="16078" href="/z/d/drug information/16078.html" rel="external">fingolimod</a> (0.5 mg daily or 1.25 mg daily) or intramuscular interferon beta-1a (30 mcg weekly) in a 1:1:1 ratio [<a href="#rid21">21</a>]. At 12 months, in the cohort of subjects who received at least one dose of a study drug, the annualized relapse rate was significantly reduced in both the high- and low-dose fingolimod groups compared with the interferon beta-1a group (0.20, 0.16, and 0.33, respectively). MRI measures also favored fingolimod. Progression of disability was infrequent in all three groups. Results from the extension phase of the TRANSFORMS trial supported a long-term benefit of fingolimod for maintaining a reduced relapse rate [<a href="#rid41">41</a>].</p><p></p><p class="headingAnchor" id="H3587641766"><span class="h2">Siponimod</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="120818" href="/z/d/drug information/120818.html" rel="external">Siponimod</a> is a S1PR modulator that is similar to but more selective than <a class="drug drug_general" data-topicid="16078" href="/z/d/drug information/16078.html" rel="external">fingolimod</a>.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indications</strong> – <a class="drug drug_general" data-topicid="120818" href="/z/d/drug information/120818.html" rel="external">Siponimod</a> is approved in the United States by the Food and Drug Administration (FDA) for the treatment of adults with CIS, RRMS, and active SPMS [<a href="#rid42">42</a>].</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="120818" href="/z/d/drug information/120818.html" rel="external">Siponimod</a> is <strong>contraindicated</strong> for patients with a <em>CYP2C9*3/*3</em> genotype (which causes substantially elevated siponimod plasma levels) or those with recent myocardial infarction, unstable angina, stroke, TIA, or advanced heart failure [<a href="#rid43">43</a>]. It is also contraindicated for patients with Mobitz type II second-degree atrioventricular (AV) block, third-degree AV block, or sick sinus syndrome, unless the patient has a functioning pacemaker. Caution is suggested for concomitant use with other antineoplastic, immune-modulating, or immunosuppressive therapies. The label advises against starting siponimod treatment after <a class="drug drug_general" data-topicid="8725" href="/z/d/drug information/8725.html" rel="external">alemtuzumab</a>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dose and administration</strong> – The starting dose of <a class="drug drug_general" data-topicid="120818" href="/z/d/drug information/120818.html" rel="external">siponimod</a> is 0.25 mg daily [<a href="#rid43">43</a>]. The first dose should be monitored for patients with sinus bradycardia, first- or second-degree (Mobitz type I) atrioventricular block, or a history of myocardial infarction or heart failure. For patients with a <em>CYP2C9*1/*3</em> or <em>*2/*3</em> genotype, the drug is titrated over a five-day period up to the maintenance dose of 1 mg daily; for patients with a <em>CYP2C9*1/*1</em>, <em>*1/*2</em>, or <em>*2/*2</em> genotype, the drug is titrated over a six-day period to the maintenance dose of 2 mg daily. Liver function and blood pressure should be monitored during treatment.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects</strong> – The most common adverse reactions with <a class="drug drug_general" data-topicid="120818" href="/z/d/drug information/120818.html" rel="external">siponimod</a> are headache, hypertension, and increased transaminase levels [<a href="#rid43">43</a>]. Siponimod causes a dose-dependent decrease in peripheral lymphocyte counts by approximately 20 to 30 percent. Potential adverse effects include infections, macular edema, bradyarrhythmia, decreased pulmonary function, liver toxicity, cutaneous malignancies, increased blood pressure, and fetal harm [<a href="#rid43">43</a>]. Although not yet reported with siponimod, rare cases of posterior reversible encephalopathy syndrome (PRES) have been associated with other S1PR modulators. Rare cases of PML and PML-IRIS have been reported in patients treated with S1PR modulators.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Screening and monitoring</strong> – Before starting <a class="drug drug_general" data-topicid="120818" href="/z/d/drug information/120818.html" rel="external">siponimod</a>, patients should have the following baseline studies [<a href="#rid43">43</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><em>CYP2C9</em> genotype</p><p class="bulletIndent2"><span class="glyph">•</span>Complete blood count and liver function test</p><p class="bulletIndent2"><span class="glyph">•</span>Ophthalmologic examination</p><p class="bulletIndent2"><span class="glyph">•</span>Varicella serology, and VZV vaccination if antibody negative for patients without a confirmed history of VZV or prior vaccination</p><p class="bulletIndent2"><span class="glyph">•</span>Cardiac evaluation, including ECG, to look for conduction system abnormalities</p><p class="bulletIndent2"><span class="glyph">•</span>Skin examination</p><p></p><p class="bulletIndent1">With <a class="drug drug_general" data-topicid="120818" href="/z/d/drug information/120818.html" rel="external">siponimod</a> treatment, the following tests and practices are recommended [<a href="#rid43">43</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Monitor for symptoms and signs of infection. Patients with subacute new or worsening symptoms should be evaluated for possible PML with brain MRI and PCR analysis of cerebrospinal fluid for the presence of JCV DNA.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>We check a complete blood count with differential including lymphocyte count before starting treatment and every six months during treatment. S1PR modulators are expected to lower the lymphocyte count by their mechanism of action. Many experts suggest consideration of therapy switch if the lymphocyte count decreases below 200 cells/microL or even 400 cells/microL.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Live attenuated vaccines should be avoided during and for four weeks after stopping <a class="drug drug_general" data-topicid="120818" href="/z/d/drug information/120818.html" rel="external">siponimod</a>.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Ophthalmologic examination should be repeated if there is any change in vision, and done routinely in patients with diabetes mellitus or a history of uveitis.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A skin examination periodically during treatment to screen for evidence of cancerous or precancerous skin lesions.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Pulmonary function tests with spirometry and DLCO, if indicated clinically.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Liver function tests for patients with symptoms suggestive of hepatic dysfunction; some experts monitor every six months during treatment even in the absence of symptoms.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Blood pressure monitoring.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Females of childbearing potential should avoid pregnancy during <a class="drug drug_general" data-topicid="120818" href="/z/d/drug information/120818.html" rel="external">siponimod</a> treatment and for 10 days after stopping siponimod [<a href="#rid43">43</a>]. (See  <a class="medical medical_review" href="/z/d/html/135221.html" rel="external">"Multiple sclerosis: Pregnancy planning", section on 'Preconception planning and care'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Stopping <a class="drug drug_general" data-topicid="120818" href="/z/d/drug information/120818.html" rel="external">siponimod</a> has been associated with rebound of MS in some patients [<a href="#rid44">44</a>], so appropriate counseling and management should be provided before cessation of medication.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy</strong> – In the six-month dose-finding BOLD trial of 297 patients with RRMS, treatment with <a class="drug drug_general" data-topicid="120818" href="/z/d/drug information/120818.html" rel="external">siponimod</a> led to reductions in MRI lesion activity [<a href="#rid45">45</a>]. In the EXPAND trial of 1651 subjects with SPMS, oral siponimod compared with placebo reduced the risk of confirmed disability progression at three months, relapse rates at 12 and 24 months, and the volume of brain lesions identified by T2-weighted MRI [<a href="#rid46">46</a>].</p><p></p><p class="headingAnchor" id="H1997611391"><span class="h2">Ozanimod</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="127521" href="/z/d/drug information/127521.html" rel="external">Ozanimod</a> is an oral S1PR modulator, a class of drugs that includes <a class="drug drug_general" data-topicid="16078" href="/z/d/drug information/16078.html" rel="external">fingolimod</a> (see <a class="local">'Fingolimod'</a> above) and <a class="drug drug_general" data-topicid="120818" href="/z/d/drug information/120818.html" rel="external">siponimod</a> (see <a class="local">'Siponimod'</a> above).</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indications</strong> – <a class="drug drug_general" data-topicid="127521" href="/z/d/drug information/127521.html" rel="external">Ozanimod</a> is indicated for the treatment of adults with relapsing forms of MS, including CIS, RRMS, and active SPMS.</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="127521" href="/z/d/drug information/127521.html" rel="external">Ozanimod</a> is <strong>contraindicated</strong> in patients with myocardial infarction, unstable angina, stroke, TIA, or heart failure in the last six months [<a href="#rid47">47</a>]. Additional contraindications include patients with Mobitz type II second-degree AV block, third-degree AV block, sick sinus syndrome or sinoatrial block (unless the patient has a functioning pacemaker), severe untreated sleep apnea, and concomitant use of a monamine oxidase inhibitor.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dose and administration</strong> – <a class="drug drug_general" data-topicid="127521" href="/z/d/drug information/127521.html" rel="external">Ozanimod</a> is titrated slowly over the first week [<a href="#rid47">47</a>]. The recommended starting dose of ozanimod is 0.23 mg once daily orally on days 1 to 4, 0.46 mg once daily on days 5 to 7, and 0.92 mg once daily on day 8 and thereafter.</p><p></p><p class="bulletIndent1">For patients with mild or moderate chronic hepatic impairment, the maintenance dose is 0.92 mg once every other day.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects – </strong>In the randomized trials, adverse events resulting in treatment discontinuation were uncommon with <a class="drug drug_general" data-topicid="127521" href="/z/d/drug information/127521.html" rel="external">ozanimod</a>; infections were similar for the ozanimod and interferon beta-1a groups [<a href="#rid48">48,49</a>]. The most common adverse reactions with ozanimod are upper respiratory infection, elevated hepatic transaminase levels, orthostatic hypotension, urinary tract infection, back pain, and hypertension [<a href="#rid47">47</a>]. Serious adverse effects include infection, bradyarrhythmia, cardiac conduction delay, liver injury, fetal risk, hypertension, and macular edema. Females of childbearing potential should use contraception during ozanimod treatment and for three months after stopping treatment. Rare cases of PML and PML-IRIS have been reported in patients treated with S1PR modulators.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Screening and monitoring</strong> – Before starting <a class="drug drug_general" data-topicid="127521" href="/z/d/drug information/127521.html" rel="external">ozanimod</a>, patients should have the following baseline studies [<a href="#rid47">47</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Complete blood count and liver function tests</p><p class="bulletIndent2"><span class="glyph">•</span>Ophthalmologic examination for patients with a history of uveitis or macular edema</p><p class="bulletIndent2"><span class="glyph">•</span>Varicella serology, and VZV vaccination if antibody negative, for patients without a confirmed history of VZV or prior vaccination</p><p class="bulletIndent2"><span class="glyph">•</span>ECG; patients with pre-existing heart conditions should have a cardiology evaluation</p><p class="bulletIndent2"><span class="glyph">•</span>Periodic skin examination is reasonable since treatment with other S1PR modulators is associated with a risk of cutaneous lesions</p><p></p><p class="bulletIndent1">With <a class="drug drug_general" data-topicid="127521" href="/z/d/drug information/127521.html" rel="external">ozanimod</a> treatment, the following tests and practices are recommended [<a href="#rid47">47</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Monitor for infection during and for three months after <a class="drug drug_general" data-topicid="127521" href="/z/d/drug information/127521.html" rel="external">ozanimod</a> treatment. Patients with subacute new or worsening symptoms should be evaluated for possible PML with brain MRI and PCR analysis of cerebrospinal fluid for the presence of JCV DNA.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>We check a complete blood count with differential including lymphocyte count before starting treatment and every six months during treatment. S1PR modulators are expected to lower the lymphocyte count by their mechanism of action. Many experts suggest consideration of therapy switch if the lymphocyte count decreases below 200 cells/microL or even 400 cells/microL.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Live attenuated vaccines should be avoided during and for up to three months after stopping <a class="drug drug_general" data-topicid="127521" href="/z/d/drug information/127521.html" rel="external">ozanimod</a>.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Ophthalmologic examination should be repeated if there is any change in vision, and done routinely in patients with diabetes mellitus or a history of uveitis.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Pulmonary function tests with spirometry and DLCO, if indicated clinically.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Monitor liver function tests every six months during treatment.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Monitor blood pressure during treatment.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Females of childbearing potential should avoid pregnancy during <a class="drug drug_general" data-topicid="127521" href="/z/d/drug information/127521.html" rel="external">ozanimod</a> treatment and for three months after stopping <a class="drug drug_general" data-topicid="120818" href="/z/d/drug information/120818.html" rel="external">siponimod</a> [<a href="#rid47">47</a>]. (See  <a class="medical medical_review" href="/z/d/html/135221.html" rel="external">"Multiple sclerosis: Pregnancy planning", section on 'Preconception planning and care'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Stopping <a class="drug drug_general" data-topicid="127521" href="/z/d/drug information/127521.html" rel="external">ozanimod</a> may be associated with rebound of MS in some patients as occurs with other S1PR modulators, so appropriate counseling and management should be provided before cessation of medication.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy</strong> – Two double-blind controlled trials (SUNBEAM [<a href="#rid48">48</a>] and RADIANCE [<a href="#rid49">49</a>]) randomly assigned patients with relapsing MS to oral <a class="drug drug_general" data-topicid="127521" href="/z/d/drug information/127521.html" rel="external">ozanimod</a> (0.5 or 1 mg daily) or to intramuscular interferon beta-1a (30 mcg weekly). In each trial, both doses of ozanimod were more effective than interferon beta-1a for reducing both the annualized relapse rate and the development of brain lesions on MRI. In the longer of the two trials (RADIANCE), the annualized relapse rates over 24 months for patients assigned to ozanimod 1 mg, ozanimod 0.5 mg, or interferon beta-1a were 0.17, 0.22, and 0.28, respectively [<a href="#rid49">49</a>]. Compared with interferon beta-1a, the risk of relapse was reduced with ozanimod 1 mg (rate ratio [RR] 0.62, 95% CI 0.51-0.77) and ozanimod 0.5 mg (RR 0.79, 95% CI 0.65-0.96).</p><p></p><p class="headingAnchor" id="H2044854143"><span class="h2">Ponesimod</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="131158" href="/z/d/drug information/131158.html" rel="external">Ponesimod</a> is an oral S1PR modulator.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indications</strong> – <a class="drug drug_general" data-topicid="131158" href="/z/d/drug information/131158.html" rel="external">Ponesimod</a> is indicated for the treatment of adults with relapsing forms of MS, including CIS, RRMS, and active SPMS [<a href="#rid50">50</a>].</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="131158" href="/z/d/drug information/131158.html" rel="external">Ponesimod</a> is <strong>contraindicated</strong> for patients with a recent (within six months) history of myocardial infarction, unstable angina, stroke, TIA, or decompensated heart failure [<a href="#rid50">50</a>]. Additional contraindications include patients with Mobitz type II second-degree AV block, third-degree AV block, or sick sinus syndrome (unless the patient has a functioning pacemaker).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dose and administration</strong> – The dose of oral <a class="drug drug_general" data-topicid="131158" href="/z/d/drug information/131158.html" rel="external">ponesimod</a> is started at 2 mg daily and slowly titrated (using a starter pack) over 15 days to a recommended maintenance dose of 20 mg once daily. Patients with sinus bradycardia or certain heart conditions should have four-hour cardiac monitoring with the first dose.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects</strong> – The most common adverse reactions with <a class="drug drug_general" data-topicid="131158" href="/z/d/drug information/131158.html" rel="external">ponesimod</a> are upper respiratory tract infections, hepatic transaminase elevations, and hypertension [<a href="#rid50">50</a>]. Serious adverse effects include infections, bradyarrhythmia, cardiac conduction delay, pulmonary effects, liver injury, fetal risk, hypertension, and macular edema. Rare cases of PML and PML-IRIS have been reported in patients treated with S1PR modulators.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Screening and monitoring</strong> – Before starting <a class="drug drug_general" data-topicid="131158" href="/z/d/drug information/131158.html" rel="external">ponesimod</a>, patients should have the following [<a href="#rid50">50</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Complete blood count including lymphocyte count</p><p class="bulletIndent2"><span class="glyph">•</span>Liver function tests</p><p class="bulletIndent2"><span class="glyph">•</span>ECG; patients with pre-existing heart conditions should have a cardiology evaluation</p><p class="bulletIndent2"><span class="glyph">•</span>Ophthalmologic evaluation</p><p class="bulletIndent2"><span class="glyph">•</span>Antibodies to VZV; seronegative patients should have VZV vaccination</p><p class="bulletIndent2"><span class="glyph">•</span>Skin examination</p><p class="bulletIndent2"><span class="glyph">•</span>Current or prior medications should be reviewed for potential additive immunosuppressant effects and for drugs that could slow the heart rate or affect atrioventricular conduction</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="131158" href="/z/d/drug information/131158.html" rel="external">Ponesimod</a> should not be started in patients with active infection.</p><p></p><p class="bulletIndent1">With <a class="drug drug_general" data-topicid="131158" href="/z/d/drug information/131158.html" rel="external">ponesimod</a> treatment, the following tests and practices are advised [<a href="#rid50">50</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Monitor for infection during <a class="drug drug_general" data-topicid="131158" href="/z/d/drug information/131158.html" rel="external">ponesimod</a> treatment and for two weeks after stopping treatment. Patients with subacute new or worsening symptoms should be evaluated for possible PML with brain MRI and PCR analysis of cerebrospinal fluid for the presence of JCV DNA.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>We check a complete blood count with differential including lymphocyte count before starting treatment and every six months during treatment. S1PR modulators are expected to lower the lymphocyte count by their mechanism of action. Many experts suggest consideration of therapy switch if the lymphocyte count decreases below 200 cells/microL or even 400 cells/microL.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Live attenuated vaccines should be avoided during and for one to two weeks after stopping <a class="drug drug_general" data-topicid="131158" href="/z/d/drug information/131158.html" rel="external">ponesimod</a>.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Ophthalmologic examination should be repeated if there is any change in vision, and done routinely in patients with diabetes mellitus or a history of uveitis.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Periodic skin examination to screen for evidence of cancerous or precancerous skin lesions.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Monitor liver function tests every six months during treatment.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Pulmonary function tests with spirometry and DLCO, if indicated clinically.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Monitor blood pressure.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Females of childbearing potential should avoid pregnancy during <a class="drug drug_general" data-topicid="131158" href="/z/d/drug information/131158.html" rel="external">ponesimod</a> treatment and for one week after stopping ponesimod. (See  <a class="medical medical_review" href="/z/d/html/135221.html" rel="external">"Multiple sclerosis: Pregnancy planning", section on 'Preconception planning and care'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Stopping <a class="drug drug_general" data-topicid="131158" href="/z/d/drug information/131158.html" rel="external">ponesimod</a> may be associated with rebound of MS in some patients [<a href="#rid50">50</a>], so appropriate counseling and management should be provided before cessation of medication.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy</strong> – Efficacy of <a class="drug drug_general" data-topicid="131158" href="/z/d/drug information/131158.html" rel="external">ponesimod</a> was established in a controlled trial that randomly assigned 1133 patients with relapsing forms of MS to treatment with ponesimod 20 mg daily or <a class="drug drug_general" data-topicid="86616" href="/z/d/drug information/86616.html" rel="external">teriflunomide</a> 14 mg daily [<a href="#rid51">51</a>]. Over a treatment period of 108 weeks, patients in the ponesimod treatment group had a lower annualized relapse rate during the study period compared with those in the teriflunomide group (0.202 versus 0.290, relative risk reduction 31 percent, absolute risk reduction 0.088), and a lower number of new or enlarging T2 lesions and a lower number of gadolinium-enhancing lesions on brain MRI [<a href="#rid50">50</a>].</p><p></p><p class="headingAnchor" id="H4018873369"><span class="h1">OTHER IMMUNOSUPPRESSANTS</span></p><p class="headingAnchor" id="H1447809235"><span class="h2">Cladribine</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9272" href="/z/d/drug information/9272.html" rel="external">Cladribine</a>, an immunosuppressive purine antimetabolite agent that targets lymphocyte subtypes, appears to reduce the relapse rate in patients with relapsing-remitting multiple sclerosis (RRMS). Cladribine was previously available in many countries, including the European Union, Canada, and Australia, before approval in the United States.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indications</strong> – <a class="drug drug_general" data-topicid="9272" href="/z/d/drug information/9272.html" rel="external">Cladribine</a> is indicated for the treatment of adults with RRMS and active secondary progressive multiple sclerosis (SPMS) [<a href="#rid52">52</a>]. Because of its adverse effect profile, cladribine is generally reserved for patients who do not tolerate or have inadequate response to other drugs for MS [<a href="#rid53">53</a>]. For the same reason, cladribine is <strong>not</strong> recommended for patients with clinically isolated syndromes (CIS) [<a href="#rid53">53</a>].</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="9272" href="/z/d/drug information/9272.html" rel="external">Cladribine</a> is <strong>contraindicated</strong> in patients with malignancy, human immunodeficiency virus (HIV), or active chronic infections. It is also contraindicated in pregnancy, breastfeeding, and for females and males of reproductive potential who do not plan to use effective contraception during treatment and for six months after the last dose in each treatment course.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dose and administration</strong> – The recommended cumulative dose of oral <a class="drug drug_general" data-topicid="9272" href="/z/d/drug information/9272.html" rel="external">cladribine</a> is 3.5 mg/kg of body weight divided into two yearly treatment courses (1.75 mg/kg per treatment course) [<a href="#rid53">53</a>]. Each treatment course is divided into two treatment cycles of four or five days separated by approximately four weeks. Lymphocyte counts must be monitored before, during, and after treatment and must be within normal limits before starting treatment and at least 800 cells/microL before starting the second treatment course.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects</strong> – The most common adverse reactions with <a class="drug drug_general" data-topicid="9272" href="/z/d/drug information/9272.html" rel="external">cladribine</a> are upper respiratory tract infections, headache, and lymphocytopenia [<a href="#rid53">53</a>]. There is also an increased risk of life-threatening infection, malignancy, and teratogenicity. Lymphocytopenia, generally mild to moderate, was more frequent among those assigned to the high- and low-dose cladribine groups (32 and 22 versus 2 percent with placebo) in the CLARITY trial [<a href="#rid54">54</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Screening and monitoring –</strong> Before starting <a class="drug drug_general" data-topicid="9272" href="/z/d/drug information/9272.html" rel="external">cladribine</a>, patients should have the following [<a href="#rid53">53</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Screening to exclude infections (HIV, tuberculosis, hepatitis B and C, acute infection), malignancy, and pregnancy</p><p class="bulletIndent2"><span class="glyph">•</span>Complete blood count with differential including lymphocyte count</p><p class="bulletIndent2"><span class="glyph">•</span>Zoster vaccination for patients who are seronegative for varicella zoster virus (VZV)</p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="115351" href="/z/d/drug information/115351.html" rel="external">Recombinant zoster vaccine</a> is recommended before or during treatment for patients who are seropositive for VZV</p><p class="bulletIndent2"><span class="glyph">•</span>All recommended immunizations; live attenuated or live vaccines should be given at least four to six weeks before starting <a class="drug drug_general" data-topicid="9272" href="/z/d/drug information/9272.html" rel="external">cladribine</a></p><p class="bulletIndent2"><span class="glyph">•</span>Baseline brain MRI, due to the risk of progressive multifocal leukoencephalopathy (PML)</p><p></p><p class="bulletIndent1">With <a class="drug drug_general" data-topicid="9272" href="/z/d/drug information/9272.html" rel="external">cladribine</a> treatment, the following tests and practices are recommended [<a href="#rid53">53</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Complete blood count and lymphocyte counts</p><p class="bulletIndent2"><span class="glyph">•</span>Anti-herpes prophylaxis for patients with lymphocyte counts &lt;200 cells/microL</p><p class="bulletIndent2"><span class="glyph">•</span>Monitor for infections</p><p class="bulletIndent2"><span class="glyph">•</span>Liver function tests prior to each treatment course</p><p class="bulletIndent2"><span class="glyph">•</span>Follow cancer screening guidelines</p><p class="bulletIndent2"><span class="glyph">•</span>Exclude pregnancy before each treatment course; provide counseling for patients planning conception</p><p class="bulletIndent2"><span class="glyph">•</span>Effective contraception during treatment and for at least six months after the last dose of each treatment course</p><p class="bulletIndent2"><span class="glyph">•</span>Diagnostic evaluation (including brain MRI) if symptoms or signs suggestive of PML</p><p class="bulletIndent2"><span class="glyph">•</span>Irradiation of cellular blood components for patients who require blood transfusion, due to the risk of graft-versus-host disease</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy</strong> – <a class="drug drug_general" data-topicid="9272" href="/z/d/drug information/9272.html" rel="external">Cladribine</a> is beneficial for patients with relapsing forms of MS, as shown by the CLARITY trial of 1326 adults with RRMS [<a href="#rid54">54</a>]. Subjects were randomly assigned in a 1:1:1 ratio to treatment with either oral cladribine (3.5 mg/kg or 5.25 mg/kg) or placebo. At 96 weeks, the annualized relapse rate was reduced on intention-to-treat analysis for both the high and low cladribine groups (0.14 and 0.15 versus 0.33 with placebo). In addition, cladribine resulted in statistically significant reductions in both the risk of sustained disability progression and brain lesion count on MRI.</p><p></p><p class="headingAnchor" id="H3118855141"><span class="h2">Teriflunomide</span><span class="headingEndMark"> — </span>The immunomodulator <a class="drug drug_general" data-topicid="86616" href="/z/d/drug information/86616.html" rel="external">teriflunomide</a> is the active metabolite of <a class="drug drug_general" data-topicid="10097" href="/z/d/drug information/10097.html" rel="external">leflunomide</a> that inhibits pyrimidine biosynthesis and disrupts the interaction of T cells with antigen presenting cells [<a href="#rid55">55</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indications</strong> – <a class="drug drug_general" data-topicid="86616" href="/z/d/drug information/86616.html" rel="external">Teriflunomide</a> is indicated for the treatment of relapsing forms of MS, including CIS, RRMS, and active SPMS.</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="86616" href="/z/d/drug information/86616.html" rel="external">Teriflunomide</a> is <strong>contraindicated</strong> in patients with severe hepatic impairment, pregnancy, hypersensitivity to teriflunomide, or current <a class="drug drug_general" data-topicid="10097" href="/z/d/drug information/10097.html" rel="external">leflunomide</a> treatment.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dose and administration</strong> – The recommended dose of oral <a class="drug drug_general" data-topicid="86616" href="/z/d/drug information/86616.html" rel="external">teriflunomide</a> is 7 mg or 14 mg once daily [<a href="#rid56">56</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects</strong> – The most common adverse effects of <a class="drug drug_general" data-topicid="86616" href="/z/d/drug information/86616.html" rel="external">teriflunomide</a> are headache, diarrhea, nausea, hair thinning, and elevated alanine aminotransferase (ALT) levels [<a href="#rid57">57-59</a>]. Uncommon but potentially serious adverse effects include hepatotoxicity, bone marrow suppression, immunosuppression, infections, hypersensitivity and serious skin reactions, peripheral neuropathy, increased blood pressure, and interstitial lung disease [<a href="#rid56">56</a>]. Teriflunomide is associated with teratogenicity and embryofetal toxicity in animal studies. Teriflunomide is also found in semen [<a href="#rid60">60</a>]. However, no evidence of fetal harm was found in pregnancy registries of babies born to couples taking the medication [<a href="#rid61">61</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Screening and monitoring</strong> – Before starting <a class="drug drug_general" data-topicid="86616" href="/z/d/drug information/86616.html" rel="external">teriflunomide</a>, patients should have the following [<a href="#rid56">56</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Liver function tests (transaminase, bilirubin) within the previous six months</p><p class="bulletIndent2"><span class="glyph">•</span>Complete blood count within the previous six months</p><p class="bulletIndent2"><span class="glyph">•</span>Screen for latent tuberculosis</p><p class="bulletIndent2"><span class="glyph">•</span>Bring patient up-to-date with all immunizations before initiating therapy with <a class="drug drug_general" data-topicid="86616" href="/z/d/drug information/86616.html" rel="external">teriflunomide</a></p><p class="bulletIndent2"><span class="glyph">•</span>Exclude pregnancy in females of reproductive potential</p><p class="bulletIndent2"><span class="glyph">•</span>Blood pressure check</p><p></p><p class="bulletIndent1">With <a class="drug drug_general" data-topicid="86616" href="/z/d/drug information/86616.html" rel="external">teriflunomide</a> treatment, the following tests and practices are recommended:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Complete blood count if signs or symptoms of infection, or if signs or symptoms of bone marrow suppression; some experts repeat the complete blood count and a comprehensive metabolic panel (which includes liver and kidney function) every six months during therapy.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Live vaccines should not be given concurrently [<a href="#rid56">56</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Monitor ALT levels at least monthly for six months after starting <a class="drug drug_general" data-topicid="86616" href="/z/d/drug information/86616.html" rel="external">teriflunomide</a>; stop treatment if transaminase increase is more than three times the upper limit of normal or if symptoms develop that are suggestive of hepatic dysfunction.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Monitor blood pressure periodically.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Effective contraception during <a class="drug drug_general" data-topicid="86616" href="/z/d/drug information/86616.html" rel="external">teriflunomide</a> treatment, followed by an accelerated drug elimination procedure after treatment.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Due to the risk of teratogenicity, females who become pregnant and males and females who wish to conceive a child should discontinue <a class="drug drug_general" data-topicid="86616" href="/z/d/drug information/86616.html" rel="external">teriflunomide</a> and undergo an accelerated drug elimination procedure using <a class="drug drug_general" data-topicid="9258" href="/z/d/drug information/9258.html" rel="external">cholestyramine</a> or activated charcoal powder for 11 days. Otherwise, teriflunomide may remain in the serum for up to two years. Pregnancy should be avoided until the serum concentration of teriflunomide is &lt;0.02 mg/L. Some practitioners avoid teriflunomide in partners of childbearing age.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy</strong> – The effectiveness of <a class="drug drug_general" data-topicid="86616" href="/z/d/drug information/86616.html" rel="external">teriflunomide</a> for the treatment of RRMS was demonstrated in the TEMSO and TOWER trials [<a href="#rid57">57,62</a>]. The TEMSO trial of 1088 adults (ages 18 to 55) with relapsing MS found that teriflunomide (either 7 mg or 14 mg once daily for just over two years) significantly reduced the annualized relapse rate by approximately 31 percent compared with placebo [<a href="#rid57">57</a>]. In addition, teriflunomide at the higher dose (14 mg daily) significantly reduced disability progression compared with placebo (27 versus 20 percent) and improved MRI measures of MS disease activity. This trial has been criticized due to a relatively high dropout rate of approximately 20 percent [<a href="#rid63">63</a>].</p><p></p><p class="bulletIndent1">In the TOWER trial of over 1100 adults (ages 18 to 55) with relapsing forms of MS, both doses of <a class="drug drug_general" data-topicid="86616" href="/z/d/drug information/86616.html" rel="external">teriflunomide</a> (7 mg or 14 mg once daily, with a median treatment duration of more than 550 days) were superior to placebo for reducing the annualized relapse rate, and teriflunomide 14 mg daily (but not 7 mg daily) barely achieved statistical significance for reducing sustained accumulation of disability compared with placebo (hazard ratio 0.68, 95% CI 0.47-1.0) [<a href="#rid62">62</a>]. This trial also had a high dropout rate of approximately 30 percent [<a href="#rid63">63</a>].</p><p></p><p class="headingAnchor" id="H249620266"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/117065.html" rel="external">"Society guideline links: Multiple sclerosis and related disorders"</a>.)</p><p class="headingAnchor" id="H2474476808"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Role of oral disease-modifying therapies (DMTs) for multiple sclerosis (MS)</strong> – There are multiple DMTs for MS, including older platform injection therapies, monoclonal antibodies, and oral agents. In general, oral DMTs are moderately effective for reducing the relapse rate and development of new brain lesions on MRI (see  <a class="medical medical_review" href="/z/d/html/1687.html" rel="external">"Initial disease-modifying therapy for relapsing-remitting multiple sclerosis in adults", section on 'Comparative efficacy'</a>); they may be preferred for patients with less active disease and for patients who value convenience using a self-administered oral medication compared with medications requiring injections or infusions. However, there is no uniform method for choosing the best DMT for an individual patient. The choice of a specific agent for patients with MS should be individualized according to disease activity, comorbid conditions, and patient values and preferences  (<a class="graphic graphic_algorithm graphicRef102519" href="/z/d/graphic/102519.html" rel="external">algorithm 1</a>). (See <a class="local">'Choosing therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fumarates</strong> – The oral fumarate DMTs include <a class="drug drug_general" data-topicid="88899" href="/z/d/drug information/88899.html" rel="external">dimethyl fumarate</a> (see <a class="local">'Dimethyl fumarate'</a> above) and bioequivalents <a class="drug drug_general" data-topicid="123109" href="/z/d/drug information/123109.html" rel="external">diroximel fumarate</a> (see <a class="local">'Diroximel fumarate'</a> above) and <a class="drug drug_general" data-topicid="128079" href="/z/d/drug information/128079.html" rel="external">monomethyl fumarate</a> (see <a class="local">'Monomethyl fumarate'</a> above). These DMTS are indicated for the treatment of relapsing forms of MS including clinically isolated syndromes (CIS), relapsing-remitting multiple sclerosis (RRMS), and active secondary progressive multiple sclerosis (SPMS). The most common adverse effects of these medications are flushing and gastrointestinal symptoms. Uncommon but serious adverse effects may include anaphylaxis, angioedema, opportunistic infections, lymphopenia, and liver injury. The dose, administration, and recommended patient screening and monitoring for use of fumarates are described above. (See <a class="local">'Fumarates'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>S1PR modulators</strong> – The oral sphingosine 1-phosphate receptor (S1PR) modulators are <a class="drug drug_general" data-topicid="16078" href="/z/d/drug information/16078.html" rel="external">fingolimod</a> (see <a class="local">'Fingolimod'</a> above), <a class="drug drug_general" data-topicid="120818" href="/z/d/drug information/120818.html" rel="external">siponimod</a> (see <a class="local">'Siponimod'</a> above), <a class="drug drug_general" data-topicid="127521" href="/z/d/drug information/127521.html" rel="external">ozanimod</a> (see <a class="local">'Ozanimod'</a> above), and <a class="drug drug_general" data-topicid="131158" href="/z/d/drug information/131158.html" rel="external">ponesimod</a> (see <a class="local">'Ponesimod'</a> above). They are indicated for the treatment of relapsing forms of MS including CIS, RRMS, and active SPMS. The most common adverse effects associated with S1PR modulators are headache, elevated liver enzymes, diarrhea, cough, flu, sinusitis, back pain, abdominal pain, and limb pain. More serious adverse effects include cardiac arrhythmias, increased blood pressure, macular edema, liver injury, diminished respiratory function, tumor development, and opportunistic infections. The dose, administration, and recommended patient screening and monitoring for use of S1PR modulators are described above. (See <a class="local">'S1PR modulators'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cladribine</strong> – <a class="drug drug_general" data-topicid="9272" href="/z/d/drug information/9272.html" rel="external">Cladribine</a>, an immunosuppressive purine antimetabolite agent that targets lymphocyte subtypes, is indicated for the treatment of adults with RRMS and active SPMS. Because of its adverse effect profile, cladribine is generally reserved for patients who do not tolerate or have inadequate response to other drugs for MS; cladribine is <strong>not</strong> recommended for patients with CIS. The most common adverse reactions with cladribine are upper respiratory tract infections, headache, and lymphocytopenia. There is also an increased risk of life-threatening infection, malignancy, and teratogenicity. The dose, administration, and recommended patient screening and monitoring for use of cladribine are described above. (See <a class="local">'Cladribine'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Teriflunomide</strong><strong> –</strong> <a class="drug drug_general" data-topicid="86616" href="/z/d/drug information/86616.html" rel="external">Teriflunomide</a> inhibits pyrimidine biosynthesis and disrupts the interaction of T cells with antigen presenting cells. It is indicated for the treatment of CIS, RRMS, and active SPMS. The most common adverse effects of teriflunomide are headache, diarrhea, nausea, hair thinning, and elevated alanine aminotransferase (ALT) levels. Teriflunomide is teratogenic. Uncommon but potentially serious adverse effects include hepatotoxicity, bone marrow suppression, immunosuppression, infections, hypersensitivity and serious skin reactions, peripheral neuropathy, increased blood pressure, and interstitial lung disease. The dose, administration, and recommended patient screening and monitoring for use of teriflunomide are described above. (See <a class="local">'Teriflunomide'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Derfuss T, Mehling M, Papadopoulou A, et al. Advances in oral immunomodulating therapies in relapsing multiple sclerosis. Lancet Neurol 2020; 19:336.</a></li><li><a class="nounderline abstract_t">Rosenkranz T, Novas M, Terborg C. PML in a patient with lymphocytopenia treated with dimethyl fumarate. N Engl J Med 2015; 372:1476.</a></li><li><a class="nounderline abstract_t">Nieuwkamp DJ, Murk JL, van Oosten BW, et al. PML in a patient without severe lymphocytopenia receiving dimethyl fumarate. N Engl J Med 2015; 372:1474.</a></li><li><a class="nounderline abstract_t">Bartsch T, Rempe T, Wrede A, et al. Progressive neurologic dysfunction in a psoriasis patient treated with dimethyl fumarate. Ann Neurol 2015; 78:501.</a></li><li><a class="nounderline abstract_t">Lehmann-Horn K, Penkert H, Grein P, et al. PML during dimethyl fumarate treatment of multiple sclerosis: How does lymphopenia matter? Neurology 2016; 87:440.</a></li><li class="breakAll">Tecfidera (dimethyl fumarate) prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/204063s032lbl.pdf (Accessed on January 09, 2024).</li><li><a class="nounderline abstract_t">Muñoz MA, Kulick CG, Kortepeter CM, et al. Liver injury associated with dimethyl fumarate in multiple sclerosis patients. Mult Scler 2017; :1352458516688351.</a></li><li><a class="nounderline abstract_t">Fox RJ, Miller DH, Phillips JT, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med 2012; 367:1087.</a></li><li><a class="nounderline abstract_t">Gold R, Kappos L, Arnold DL, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med 2012; 367:1098.</a></li><li><a class="nounderline abstract_t">Xu Z, Zhang F, Sun F, et al. Dimethyl fumarate for multiple sclerosis. Cochrane Database Syst Rev 2015; :CD011076.</a></li><li class="breakAll">Vumerity (diroximel fumarate) delayed-release capsules prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211855s016lbl.pdf (Accessed on January 09, 2024).</li><li class="breakAll">FDA clears more tolerable diroximel fumarate (Vumerity) for MS. https://www.medscape.com/viewarticle/920574 (Accessed on May 04, 2020).</li><li><a class="nounderline abstract_t">Naismith RT, Wundes A, Ziemssen T, et al. Diroximel Fumarate Demonstrates an Improved Gastrointestinal Tolerability Profile Compared with Dimethyl Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III EVOLVE-MS-2 Study. CNS Drugs 2020; 34:185.</a></li><li class="breakAll">FDA approves Bafiertam, Tecfidera generic, for relapsing MS. https://multiplesclerosisnewstoday.com/news-posts/2020/05/04/fda-approves-bafiertam-tecfidera-generic-to-treat-relapsing-ms/ (Accessed on May 05, 2020).</li><li class="breakAll">Bafiertam (monomethyl fumarate) delayed-release capsules, prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/210296s005lbl.pdf (Accessed on January 09, 2024).</li><li><a class="nounderline abstract_t">McGinley MP, Cohen JA. Sphingosine 1-phosphate receptor modulators in multiple sclerosis and other conditions. Lancet 2021; 398:1184.</a></li><li><a class="nounderline abstract_t">Cohen JA, Chun J. Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis. Ann Neurol 2011; 69:759.</a></li><li class="breakAll">Gilenya (fingolimod) capsules; labeling-package insert. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/022527s038lbl.pdf (Accessed on October 03, 2023).</li><li class="breakAll">Tascenso ODT (fingolimod) orally disintegrating tablets; labeling-package insert. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/214962s000lbl.pdf (Accessed on January 03, 2023).</li><li><a class="nounderline abstract_t">Kappos L, Radue EW, O'Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010; 362:387.</a></li><li><a class="nounderline abstract_t">Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010; 362:402.</a></li><li><a class="nounderline abstract_t">Jain N, Bhatti MT. Fingolimod-associated macular edema: incidence, detection, and management. Neurology 2012; 78:672.</a></li><li><a class="nounderline abstract_t">Fragoso YD. Multiple sclerosis treatment with fingolimod: profile of non-cardiologic adverse events. Acta Neurol Belg 2017; 117:821.</a></li><li><a class="nounderline abstract_t">Arvin AM, Wolinsky JS, Kappos L, et al. Varicella-zoster virus infections in patients treated with fingolimod: risk assessment and consensus recommendations for management. JAMA Neurol 2015; 72:31.</a></li><li><a class="nounderline abstract_t">Gross CM, Baumgartner A, Rauer S, Stich O. Multiple sclerosis rebound following herpes zoster infection and suspension of fingolimod. Neurology 2012; 79:2006.</a></li><li><a class="nounderline abstract_t">Ratchford JN, Costello K, Reich DS, Calabresi PA. Varicella-zoster virus encephalitis and vasculopathy in a patient treated with fingolimod. Neurology 2012; 79:2002.</a></li><li><a class="nounderline abstract_t">Achtnichts L, Obreja O, Conen A, et al. Cryptococcal Meningoencephalitis in a Patient With Multiple Sclerosis Treated With Fingolimod. JAMA Neurol 2015; 72:1203.</a></li><li><a class="nounderline abstract_t">Huang D. Disseminated cryptococcosis in a patient with multiple sclerosis treated with fingolimod. Neurology 2015; 85:1001.</a></li><li class="breakAll">Gilenya (fingolimod): Drug Safety Communication - FDA warns about cases of rare brain infection. http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm457183.htm (Accessed on August 04, 2015).</li><li><a class="nounderline abstract_t">Gyang TV, Hamel J, Goodman AD, et al. Fingolimod-associated PML in a patient with prior immunosuppression. Neurology 2016; 86:1843.</a></li><li><a class="nounderline abstract_t">Berger JR, Cree BA, Greenberg B, et al. Progressive multifocal leukoencephalopathy after fingolimod treatment. Neurology 2018; 90:e1815.</a></li><li class="breakAll">FDA warns about severe worsening of multiple sclerosis after stopping the medicine Gilenya (fingolimod). https://www.fda.gov/Drugs/DrugSafety/ucm626095.htm (Accessed on November 21, 2018).</li><li><a class="nounderline abstract_t">Hatcher SE, Waubant E, Nourbakhsh B, et al. Rebound Syndrome in Patients With Multiple Sclerosis After Cessation of Fingolimod Treatment. JAMA Neurol 2016; 73:790.</a></li><li><a class="nounderline abstract_t">Visser F, Wattjes MP, Pouwels PJ, et al. Tumefactive multiple sclerosis lesions under fingolimod treatment. Neurology 2012; 79:2000.</a></li><li><a class="nounderline abstract_t">Centonze D, Rossi S, Rinaldi F, Gallo P. Severe relapses under fingolimod treatment prescribed after natalizumab. Neurology 2012; 79:2004.</a></li><li><a class="nounderline abstract_t">Pilz G, Harrer A, Wipfler P, et al. Tumefactive MS lesions under fingolimod: a case report and literature review. Neurology 2013; 81:1654.</a></li><li class="breakAll">Geissbühler H, Butzkueven S, Hernández-Diaz K, et al. Pregnancy outcomes from fingolimod clinical trials and post-marketing experience and the need for a multinational Gilenya (fingolimod) Pregnancy Exposure Registry in multiple sclerosis. 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, 2012. </li><li><a class="nounderline abstract_t">Karlsson G, Francis G, Koren G, et al. Pregnancy outcomes in the clinical development program of fingolimod in multiple sclerosis. Neurology 2014; 82:674.</a></li><li><a class="nounderline abstract_t">La Mantia L, Tramacere I, Firwana B, et al. Fingolimod for relapsing-remitting multiple sclerosis. Cochrane Database Syst Rev 2016; 4:CD009371.</a></li><li><a class="nounderline abstract_t">Kappos L, O'Connor P, Radue EW, et al. Long-term effects of fingolimod in multiple sclerosis: the randomized FREEDOMS extension trial. Neurology 2015; 84:1582.</a></li><li><a class="nounderline abstract_t">Cohen JA, Khatri B, Barkhof F, et al. Long-term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS study. J Neurol Neurosurg Psychiatry 2016; 87:468.</a></li><li class="breakAll">FDA approves new oral drug to treat multiple sclerosis. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm634469.htm (Accessed on April 02, 2019).</li><li class="breakAll">Mayzent (siponimod) tablets, prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/209884s015lbl.pdf (Accessed on February 02, 2023).</li><li><a class="nounderline abstract_t">Litwin T, Smoliński Ł, Członkowka A. Substantial disease exacerbation in a patient with relapsing-remitting multiple sclerosis after withdrawal from siponimod. Neurol Neurochir Pol 2018; 52:98.</a></li><li><a class="nounderline abstract_t">Selmaj K, Li DK, Hartung HP, et al. Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study. Lancet Neurol 2013; 12:756.</a></li><li><a class="nounderline abstract_t">Kappos L, Bar-Or A, Cree BAC, et al. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. Lancet 2018; 391:1263.</a></li><li class="breakAll">Zeposia (ozanimod) capsules precribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/209899s006s009lbl.pdf (Accessed on October 26, 2023).</li><li><a class="nounderline abstract_t">Comi G, Kappos L, Selmaj KW, et al. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial. Lancet Neurol 2019; 18:1009.</a></li><li><a class="nounderline abstract_t">Cohen JA, Comi G, Selmaj KW, et al. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial. Lancet Neurol 2019; 18:1021.</a></li><li class="breakAll">Ponvory (ponesimod) prescribing information. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213498s004lbl.pdf (Accessed on October 27, 2023).</li><li><a class="nounderline abstract_t">Kappos L, Fox RJ, Burcklen M, et al. Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study: A Randomized Clinical Trial. JAMA Neurol 2021; 78:558.</a></li><li class="breakAll">FDA approves new oral treatment for multiple sclerosis. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm634837.htm (Accessed on April 03, 2019).</li><li class="breakAll">Prescribing information Mavenclad (cladribine) tablets. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/022561s006lbl.pdf (Accessed on October 20, 2022).</li><li><a class="nounderline abstract_t">Giovannoni G, Comi G, Cook S, et al. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med 2010; 362:416.</a></li><li><a class="nounderline abstract_t">Zeyda M, Poglitsch M, Geyeregger R, et al. Disruption of the interaction of T cells with antigen-presenting cells by the active leflunomide metabolite teriflunomide: involvement of impaired integrin activation and immunologic synapse formation. Arthritis Rheum 2005; 52:2730.</a></li><li class="breakAll">Teriflunomide prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/202992s013s015lbl.pdf (Accessed on October 27, 2023).</li><li><a class="nounderline abstract_t">O'Connor P, Wolinsky JS, Confavreux C, et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med 2011; 365:1293.</a></li><li><a class="nounderline abstract_t">O'Connor PW, Li D, Freedman MS, et al. A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses. Neurology 2006; 66:894.</a></li><li><a class="nounderline abstract_t">O'Connor P, Comi G, Freedman MS, et al. Long-term safety and efficacy of teriflunomide: Nine-year follow-up of the randomized TEMSO study. Neurology 2016; 86:920.</a></li><li><a class="nounderline abstract_t">New drugs for relapsing multiple sclerosis. Med Lett Drugs Ther 2012; 54:89.</a></li><li><a class="nounderline abstract_t">Vukusic S, Coyle PK, Jurgensen S, et al. Pregnancy outcomes in patients with multiple sclerosis treated with teriflunomide: Clinical study data and 5 years of post-marketing experience. Mult Scler 2020; 26:829.</a></li><li><a class="nounderline abstract_t">Confavreux C, O'Connor P, Comi G, et al. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol 2014; 13:247.</a></li><li><a class="nounderline abstract_t">He D, Zhang C, Zhao X, et al. Teriflunomide for multiple sclerosis. Cochrane Database Syst Rev 2016; 3:CD009882.</a></li></ol></div><div id="topicVersionRevision">Topic 143125 Version 3.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32059809" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Advances in oral immunomodulating therapies in relapsing multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25853765" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : PML in a patient with lymphocytopenia treated with dimethyl fumarate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25853764" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : PML in a patient without severe lymphocytopenia receiving dimethyl fumarate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26150206" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Progressive neurologic dysfunction in a psoriasis patient treated with dimethyl fumarate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27343070" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : PML during dimethyl fumarate treatment of multiple sclerosis: How does lymphopenia matter?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27343070" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : PML during dimethyl fumarate treatment of multiple sclerosis: How does lymphopenia matter?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28086032" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Liver injury associated with dimethyl fumarate in multiple sclerosis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22992072" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22992073" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25900414" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Dimethyl fumarate for multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25900414" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Dimethyl fumarate for multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25900414" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Dimethyl fumarate for multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31953790" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Diroximel Fumarate Demonstrates an Improved Gastrointestinal Tolerability Profile Compared with Dimethyl Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III EVOLVE-MS-2 Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31953790" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Diroximel Fumarate Demonstrates an Improved Gastrointestinal Tolerability Profile Compared with Dimethyl Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III EVOLVE-MS-2 Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31953790" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Diroximel Fumarate Demonstrates an Improved Gastrointestinal Tolerability Profile Compared with Dimethyl Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III EVOLVE-MS-2 Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34175020" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Sphingosine 1-phosphate receptor modulators in multiple sclerosis and other conditions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21520239" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21520239" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21520239" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20089952" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20089954" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22371414" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Fingolimod-associated macular edema: incidence, detection, and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28528469" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Multiple sclerosis treatment with fingolimod: profile of non-cardiologic adverse events.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25419615" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Varicella-zoster virus infections in patients treated with fingolimod: risk assessment and consensus recommendations for management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23035074" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Multiple sclerosis rebound following herpes zoster infection and suspension of fingolimod.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23035072" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Varicella-zoster virus encephalitis and vasculopathy in a patient treated with fingolimod.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26457631" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Cryptococcal Meningoencephalitis in a Patient With Multiple Sclerosis Treated With Fingolimod.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26291283" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Disseminated cryptococcosis in a patient with multiple sclerosis treated with fingolimod.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26291283" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Disseminated cryptococcosis in a patient with multiple sclerosis treated with fingolimod.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27164718" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Fingolimod-associated PML in a patient with prior immunosuppression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29669908" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Progressive multifocal leukoencephalopathy after fingolimod treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29669908" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Progressive multifocal leukoencephalopathy after fingolimod treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27135594" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Rebound Syndrome in Patients With Multiple Sclerosis After Cessation of Fingolimod Treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23035065" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Tumefactive multiple sclerosis lesions under fingolimod treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23035063" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Severe relapses under fingolimod treatment prescribed after natalizumab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24097813" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Tumefactive MS lesions under fingolimod: a case report and literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24097813" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Tumefactive MS lesions under fingolimod: a case report and literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24463630" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Pregnancy outcomes in the clinical development program of fingolimod in multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27091121" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Fingolimod for relapsing-remitting multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25795646" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Long-term effects of fingolimod in multiple sclerosis: the randomized FREEDOMS extension trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26111826" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Long-term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26111826" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Long-term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26111826" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Long-term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29110882" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Substantial disease exacerbation in a patient with relapsing-remitting multiple sclerosis after withdrawal from siponimod.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23764350" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29576505" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29576505" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31492651" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31492652" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31492652" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33779698" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33779698" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33779698" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20089960" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16142756" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Disruption of the interaction of T cells with antigen-presenting cells by the active leflunomide metabolite teriflunomide: involvement of impaired integrin activation and immunologic synapse formation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16142756" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Disruption of the interaction of T cells with antigen-presenting cells by the active leflunomide metabolite teriflunomide: involvement of impaired integrin activation and immunologic synapse formation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21991951" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Randomized trial of oral teriflunomide for relapsing multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16567708" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26865517" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Long-term safety and efficacy of teriflunomide: Nine-year follow-up of the randomized TEMSO study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23183318" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : New drugs for relapsing multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30968734" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Pregnancy outcomes in patients with multiple sclerosis treated with teriflunomide: Clinical study data and 5 years of post-marketing experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24461574" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27003123" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Teriflunomide for multiple sclerosis.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
